Soft Tissue Sarcoma
George D. Demetri(Dana-Farber Cancer Institute), Jeffrey D. Wayne(Northwestern University), Thomas F. DeLaney, Marilyn M. Bui, Kristen N. Ganjoo(Stanford Medicine), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Scott Antonia(Moffitt Cancer Center), I. Benjamin Paz, R. Lor Randall, Raymond J. Hutchinson(Children's Hospital of Los Angeles), Raphael E. Pollock(The University of Texas MD Anderson Cancer Center), Sean V. McGarry(City of Hope), Martin J. Heslin(City of Hope), Richard F. Riedel(Daiichi-Sankyo (South Korea)), G. Douglas Letson(Moffitt Cancer Center), Margaret von Mehren(Fox Chase Cancer Center), Richard J. OʼDonnell(The University of Texas MD Anderson Cancer Center), John M. Kane(Roswell Park Comprehensive Cancer Center), Karen D. Schupak, Ernest U. Conrad, John D. Pfeifer(Washington University in St. Louis), Ephraim S. Casper(Cornell University), Herbert S. Schwartz(The University of Texas MD Anderson Cancer Center)
Cited by 167
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k